Lionbridge Secures Four-Year Sole Supplier Agreement With World-Leading Pharmaceutical Company Estimated At $80-100 Million

Comprehensive, global-scale translation program to drive efficiency, global compliance and innovation across 100 global markets

WALTHAM, Mass. – October 01, 2014Lionbridge Technologies, Inc. (Nasdaq: LIOX), today announced that it has secured a new, four year contract with a world-leading research-based pharmaceutical and healthcare company valued at approximately $80- $100 million. With this agreement, Lionbridge will be the sole provider of global translation services across more than 90 languages. Through its proven global program management and highly-secure, cloud technology platforms, Lionbridge will support all of the client’s global content including clinical and regulatory materials, global communications, partner, training and development, legal and human resources content.

The client will rely on Lionbridge’s global scale expertise in life sciences, proven language technology platforms and strong project management and governance processes to drive the highest levels of efficiency, compliance, transparency and excellence across its global markets.

To support the client’s program worldwide, Lionbridge will combine cloud-based language management and workflow platforms with globally-aligned program management across its 38 offices in 26 countries.

“With a proven track record of managing complex global programs in highly-regulated environments, we are delighted this global pharma leader chose Lionbridge as its partner,” said Rory Cowan, CEO, Lionbridge. “We look forward to becoming a trusted, valuable partner for this client as our teams support their mission to help people do more, feel better, live longer.”

Lionbridge Life Sciences is a strategic practice of Lionbridge focusing on high-quality translation services, sophisticated linguistic validation and best-in-class solutions for Pharmaceutical, Medical Device, Clinical Research Organizations (CROs), Medical Publishing and Healthcare companies. Lionbridge life sciences teams work collaboratively with clients to turn sensitive, complex and frequently challenging content into highly relevant communications for local markets and regulating agencies across the world.

About Lionbridge

Lionbridge enables more than 800 world-leading brands to increase international market share, speed adoption of products and effectively engage their customers in local markets worldwide. Using our innovative cloud technology platforms and our global crowd of more than 100,000 professional cloud workers, we provide translation, online marketing, application testing, global content creation and management solutions that ensure global brand consistency, local relevancy and technical usability across all touch points of the customer lifecycle. Based in Waltham, Mass., Lionbridge maintains solution centers in 27 countries. To learn more, visit


Sara Buda
(781) 434-6190

Forward-Looking Statements

This press release contains express or implied forward-looking statements, including statements relating to estimated revenues associated with the customer engagement referenced in this release. Lionbridge’s actual experiences and results may differ materially from those discussed in the forward-looking statements. Factors that might cause such a difference include; the termination of this contract or particular engagements prior to the end of their term; delays in ramp of customer programs; changes in forecast or demand for services by the customer or its partners, including as a result of regulatory changes affecting the pharmaceutical industry; changes in business or research strategies and investments by the customer; the size, timing and recognition of revenue; continued uncertainty, volatility or deterioration in global economic conditions that could negatively affect demand for the Company’s services; continued fluctuations in political, economic and business conditions, and additional downturns in worldwide economic conditions generally, and in the information technology and software industries specifically; Lionbridge’s ability to forecast revenue, profitability and customer demand; Lionbridge’s ability to perform services in lower cost operational locations; and customer delays or postponements of services. For a more detailed description of the risk factors associated with Lionbridge, Please refer to Lionbridge’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2014.